| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168616 | NOVARTIS | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
Jul, 2026
(2 years from now) | |
Valturna is owned by Novartis.
Valturna contains Aliskiren Hemifumarate; Valsartan.
Valturna has a total of 1 drug patent out of which 0 drug patents have expired.
Valturna was authorised for market use on 16 September, 2009.
Valturna is available in tablet;oral dosage forms.
The generics of Valturna are possible to be released after 03 July, 2026.
Drugs and Companies using ALISKIREN HEMIFUMARATE; VALSARTAN ingredient
Market Authorisation Date: 16 September, 2009
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
VALTURNA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic